Connect with us

News

Artificial insemination kit granted FDA clearance

Mosie Baby becomes the first company to receive FDA clearance for at-home intravaginal insemination

Published

on

The US fertility start-up Mosie Baby has received FDA Class II clearance for its at-home insemination kit.

The kit, selected by the Bill and Melinda Gates Foundation to be part of the Designing Motherhood exhibition at the Discovery Center Museum in Seattle, aims to support those unable to conceive with intercourse or for whom intercourse is not an option.

Designed to be used with either a fresh or cryogenically frozen donor semen sample, each kit includes two syringes for at-home insemination and two collection cups for semen collection. The product is the first and only FDA-cleared over-the-counter kit for use in intravaginal insemination (IVI).

“Nearly 10 years ago, my husband and I were devastated by a diagnosis of unexplained infertility and were desperate for options that were safe, financially accessible and easy to use at home,” said co-founder and CEO Maureen Brown.

“Since inventing the Mosie Baby Kit in 2014, we realised we weren’t alone in our fertility journey as it is reported that one in six people experience infertility. To date, we’re very proud to share that Mosie Baby has helped more than 100,000 families inseminate from the comfort of their own home.

“We are now thrilled to offer our device as an FDA reviewed option for families looking to inseminate at home.”

Kwame Ulmer, managing partner at MedTech Impact Partners and former deputy director at FDA, said: “The recent Mosie Baby clearance means hundreds of thousands of underserved people now benefit from an at home option.

“The technology adheres to the highest FDA recognised test standards and is supported by robust clinical performance testing. The team took the time and care to manufacture a quality product.

“I am delighted to see it become accessible to countless future parents on their fertility journey. The team at Mosie Baby is on a path to becoming the at home gold standard fertility option.”

Following its FDA 510k Class II clearance, Mosie Baby is planning to expand access to its insemination kit, aiming to democratise access to family building and eliminate stigma associated with insemination.

The Mosie Baby insemination kit is available for purchase at mosiebaby.com, CVS.com or at select CVS stores nationwide. The kit is expected to launch with additional retailers and healthcare partners in 2024.

To receive the Femtech World newsletter, sign up here.

Fertility

AI patch could detect hidden hormone disruptions behind unexplained infertility

Published

on

Even when standard clinical tests show normal hormone levels, men and women may have hidden problems in how their reproductive hormones are timed and coordinated, potentially affecting fertility, new research suggests.

The findings suggest reproductive health may depend not only on hormone levels in the bloodstream but also on the rhythm, timing and synchronisation of hormone changes across hours, days and the menstrual cycle.

Researchers said a wearable skin sensor patch, combined with artificial intelligence, could help detect endocrine dysfunction earlier and support more personalised fertility care.

Unexplained infertility affects about 15 to 30 per cent of couples and is diagnosed when standard investigations reveal no clear cause.

In men, current tests for infertility or hypogonadism, defined clinically as low testosterone, often include a single morning serum testosterone measurement.

In women, fertility assessment typically examines menstrual cycle characteristics and reproductive hormones such as luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone.

However, reproductive hormones are not static markers. They are dynamic biological signals that rise and fall in regulated patterns throughout the day and across the menstrual cycle.

Testosterone, for example, follows a diurnal rhythm, meaning it changes across the day, while female reproductive hormones act through coordinated feedback loops involving the hypothalamic, pituitary and ovarian systems.

A single blood test may therefore miss clinically important disruption in hormonal timing.

In one study, Dr Tinatin Kutchukhidze, from the University of Oxford, examined 102 men in Georgia and the UK.

The participants were aged 22 to 38 and had normal morning total testosterone levels, measured at 12 to 35 nanomoles per litre, with or without infertility or symptoms of hypogonadism.

Hypogonadism is a condition in which the body produces too little testosterone or other sex hormones.

Kutchukhidze and colleagues used wearable AI-enabled skin sensor patches to measure testosterone levels every 15 minutes across four days.

The team found that men with symptoms had significantly disrupted testosterone rhythms, despite standard laboratory tests showing normal testosterone levels.

These previously undetected rhythm abnormalities were also associated with reduced sperm concentration and symptoms of androgen deficiency.

Androgens are hormones, including testosterone, that play an important role in reproductive health.

Kutchukhidze said: “For the first time, we have been able to track androgen patterns in real time across several days with a novel, non-invasive, continuous, AI-driven testosterone monitoring patch, compatible with Android and iPhone mobile devices.

“Previous research suggests that a normal morning testosterone level is sufficient to exclude clinically significant androgen deficiency. However, our findings challenge that assumption by demonstrating that men with normal serum testosterone may still exhibit marked disturbances in hormonal rhythmicity associated with reproductive dysfunction.”

According to the abstract, the study compared 54 men with infertility or hypogonadal symptoms with 48 age-matched healthy controls.

Mean morning serum testosterone did not differ significantly between symptomatic men and controls, at 22.4 ± 3.1 compared with 23.1 ± 3.5 nanomoles per litre.

Continuous AI-assisted monitoring, however, revealed significant differences in androgen dynamics.

Men with symptoms had lower diurnal amplitude than controls, at 5.2 ± 1.1 compared with 8.7 ± 1.4 nanomoles per litre.

The AI-derived rhythm indices predicted subclinical dysfunction with an area under the curve of 0.87, compared with 0.61 for static serum testosterone testing.

In diagnostic research, the area under the curve is used to assess how well a test distinguishes between groups, with higher values indicating stronger discrimination.

A second study by Kutchukhidze’s team examined female reproductive hormone rhythms.

The researchers developed an AI-driven metric called Endocrine Rhythm Integrity to assess whether reproductive hormones were changing in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle.

Endocrine refers to the hormone system, while endocrine dysfunction means hormones are not being produced or regulated in a typical way.

The team analysed data from 312 women aged 18 to 22 who had self-reported regular menstrual cycles.

Participants included fertile controls and women with unexplained infertility.

The researchers assessed key reproductive hormones during the luteal phase, including luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone.

The luteal phase is the part of the menstrual cycle after ovulation. Ovulation is the release of an egg from the ovary.

They also incorporated physiological data such as basal body temperature, heart rate and sleep patterns.

Basal body temperature is the body’s resting temperature and can shift slightly around ovulation.

The study found that women with unexplained infertility had lower Endocrine Rhythm Integrity scores even when conventional hormone levels appeared normal.

Lower scores predicted infertility and were also associated with a higher incidence of implantation failure, when an embryo does not successfully attach to the womb lining.

Kutchukhidze said: “Our study reveals that a woman may have a seemingly healthy menstrual cycle and normal hormone levels but still experience hidden endocrine dysfunction that affects her ability to conceive.

“Rather than analysing hormone levels as isolated values, Endocrine Rhythm Integrity evaluates whether reproductive hormones are changing in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle.”

In the female study, mean cycle length did not differ significantly between fertile and infertile groups, at 28.9 ± 2.3 compared with 28.9 ± 2.5 days.

Endocrine Rhythm Integrity scores, however, were lower in the infertility group, at 0.61 ± 0.12 compared with 0.78 ± 0.10.

Disrupted endocrine rhythm integrity was observed in 64 per cent of infertile participants despite hormonally normal mid-luteal progesterone levels.

The metric independently predicted infertility status after adjustment for age, body mass index and anti-Müllerian hormone.

Anti-Müllerian hormone is made by reproductive tissues and is best known as a marker of ovarian reserve, meaning an estimate of the number of eggs remaining in the ovaries.

Receiver operating characteristic analysis indicated that Endocrine Rhythm Integrity identified infertility more effectively than cycle length or single-time-point progesterone assessment.

Lower Endocrine Rhythm Integrity scores were also associated with a higher incidence of implantation failure.

Kutchukhidze said: “Our AI-driven rhythm analyses were significantly better at identifying subclinical reproductive dysfunction than conventional testing, suggesting that both female and male endocrine disorders may not simply be disorders of hormone quantity, but rather disorders of hormonal timing, synchronisation and biological rhythm.”

The team will next assess whether the tool can reliably predict fertility outcomes across different reproductive conditions in larger and more diverse populations.

Continue Reading

Pregnancy

Type 2 diabetes raising twice as fast in younger womem, research finds

Published

on

Type 2 diabetes diagnoses are rising twice as fast in women under 40 as in women over 40, new data shows.

Type 2 diabetes is a serious condition and can lead to complications such as heart attacks and strokes. When it develops in younger people, it can be more aggressive and have more severe and acute effects.

Diagnoses in women under 40 rose by 47 per cent between 2017/18 and 2023/24. By comparison, diagnoses rose by 22 per cent in women aged 40 to 79.

During the same period, type 2 diabetes diagnoses in men under 40 increased by 34 per cent.

Diabetes UK said it is concerned about the follow-up care offered to women who have had gestational diabetes, also known as GDM, which increases the risk of developing type 2 diabetes after pregnancy.

Gestational diabetes is high blood sugar that develops during pregnancy and usually goes away after birth, but it raises the risk of type 2 diabetes later.

Colette Marshall, chief executive at Diabetes UK, said: “These figures should be a wake-up call. Type 2 diabetes is rising twice as fast in younger women compared to older women, and a crucial opportunity for prevention is being missed. Every diagnosis is life-changing, but when it develops in younger people, type 2 diabetes is even more aggressive.

“Pregnancy shouldn’t be a pathway to ill health. Yet despite facing a much higher risk of type 2 diabetes, too many women with GDM receive little or no follow-up care after pregnancy.

“As the Government turns its Strategy into action, support for women who have had gestational diabetes must not be overlooked.”

Last year, the NHS published the first national GDM audit for England in 2024/25, which revealed inconsistencies in follow-up care.

Only 57 per cent of women with GDM received an annual HbA1c test, which should be offered to every woman with GDM.

An HbA1c test measures average blood sugar levels over the previous two to three months.

Only 4.5 per cent of women had received support through the NHS Diabetes Prevention Programme.

The report also found that 11 per cent of women developed prediabetes within five years of having GDM, while 15 per cent developed type 2 diabetes within 10 years.

Prediabetes means blood sugar levels are higher than normal and a person has a higher risk of developing type 2 diabetes.

A recent survey funded by Diabetes UK also found that more than a third of women with GDM felt abandoned by healthcare services after giving birth.

If you live in England and have had gestational diabetes, you can self-refer to the NHS Diabetes Prevention Programme, which supports people at risk of developing type 2 diabetes. If you live in Northern Ireland, Scotland or Wales, you can speak to your GP about support.

Diabetes UK has written to women’s health minister Baroness Merron calling for urgent improvements to postnatal support for those diagnosed with GDM during pregnancy.

GDM affects between 10 and 20 per cent of pregnant women, but Diabetes UK said cases have long been underreported and UK-wide data on the condition has not been readily available.

The charity said poor follow-up care for women who have had GDM may be contributing to rising rates of type 2 diabetes in younger women.

It is calling for consistent postnatal follow-ups for women after GDM, more referrals to the NHS Diabetes Prevention Programme, greater accountability for improvements in postnatal care, and action on inequalities affecting women from deprived and minority ethnic communities.

Continue Reading

News

Smartwatch data helps researchers study menopause transition

Published

on

Smartwatch data may help track menopause sleep changes after researchers analysed more than 94,000 nights of Apple Watch sleep records.

The study analysed more than 94,000 nights of sleep data from 338 participants in the Apple Women’s Health Study.

It found that many participants spent more time awake during the night in the 12 months before and after their final logged menstrual period.

For the past several years, Apple has used the Apple Watch to support large-scale health studies through the Apple Research app.

These include the Apple Women’s Health Study, the Apple Heart and Movement Study, and the Apple Hearing Study, which launched in 2019 with research partners including Harvard, Brigham and Women’s Hospital, the American Heart Association and the University of Michigan.

In February 2025, Apple said those studies had grown to more than 350,000 participants across the US.

Recently, researchers at Harvard T.H. Chan School of Public Health published results on how sleep patterns change during perimenopause.

The study looked at wake after sleep onset, or WASO, which measures how much time a person spends awake after first falling asleep.

In the 18 months leading up to menopause, 60 per cent of women with sleep tracking data showed increased WASO compared with the previous six months.

The average increase was 7 per cent.

Researchers also found that, in the 12 months before and after the last logged menstrual period, participants spent about 0.8 per cent more of their sleep time awake after menopause than before.

However, the findings varied widely between participants.

Some women had much larger increases in time awake after menopause, while others had no meaningful sleep change at all.

The researchers said this reflects the fact that each person experiences perimenopause and menopause differently.

Participants who tracked sleep also logged menopause symptoms.

Hot flushes were reported by 82.3 per cent of participants, irritability by 68.1 per cent, mental exhaustion by 65.7 per cent and sexual symptoms by 65.6 per cent.

Among participants with more severe menopause symptoms, the symptoms most closely linked with worse sleep were bladder symptoms, joint symptoms, heart discomfort and depressive symptoms.

The researchers also shared recommendations that may help women sleep better during perimenopause.

These include maintaining a cool sleeping environment, keeping a consistent sleep schedule, getting regular movement, avoiding common bladder irritants and limiting fluids in the hours before bedtime, and prioritising relaxation or mindfulness techniques as part of a bedtime routine.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.